Tsumura & Co. (TSMRF)
- Previous Close
0.00 - Open
28.15 - Bid 22.95 x 40000
- Ask 26.05 x 40000
- Day's Range
28.15 - 28.15 - 52 Week Range
26.76 - 28.15 - Volume
100 - Avg. Volume
0 - Market Cap (intraday)
2.369B - Beta (5Y Monthly) 0.03
- PE Ratio (TTM)
13.03 - EPS (TTM)
2.16 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield 0.88 (3.11%)
- Ex-Dividend Date Sep 29, 2025
- 1y Target Est
--
Tsumura & Co. manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally. The company offers Kampo extract intermediates, granular and prescription Kampo formulations, over-the-counter Kampo medicine, other medications, and herbal bath salts. It offers its products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation, hemorrhoid, body aches, cold, cough, nasal/throat inflammation, children's sickness, stress, and urinary problems. Tsumura & Co. was founded in 1893 and is headquartered in Tokyo, Japan.
www.tsumura.co.jp--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: TSMRF
View MorePerformance Overview: TSMRF
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSMRF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSMRF
View MoreValuation Measures
Market Cap
1.84B
Enterprise Value
1.82B
Trailing P/E
13.02
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.99
Price/Book (mrq)
1.12
Enterprise Value/Revenue
2.14
Enterprise Value/EBITDA
7.38
Financial Highlights
Profitability and Income Statement
Profit Margin
17.91%
Return on Assets (ttm)
5.62%
Return on Equity (ttm)
11.04%
Revenue (ttm)
181.09B
Net Income Avi to Common (ttm)
32.43B
Diluted EPS (ttm)
2.16
Balance Sheet and Cash Flow
Total Cash (mrq)
73.23B
Total Debt/Equity (mrq)
21.31%
Levered Free Cash Flow (ttm)
251M